with Fmoc-protected 3-iodopropyl-amine, followed by ring opening with 2-trimethylsilylethanol. After Fmoc cleavage by HNEt2, the histidine amine derivative was coupled to biotin, to the pentapeptide leucine-enkephalin and to Vitamin B12-b-acid by amide formation, employing TBTU as the coupling reagent. In order to make the histidine accessible for labelling, the teoc protecting group was removed by either NBu4F (for the biotin conjugate) or by TFA (for the enkephalin and B12 conjugates). Reaction of a 10(-4) M solution of the bioconjugates with [99mTc(H2O)3(CO)3]+ at 50 degrees C for 30 min led to the formation of one single new peak in the HPLC radiochromatogram in each case, confirming quantitative labelling of the respective biomolecules. To assess the nature of the labelled compounds, the rhenium analogues with Re(CO)3 were also synthesised and similar retention times confirmed the identity with the 99mTc labelled conjugates. The new histidine derivative 3-{1-[3-(9H-fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-imidazol-4-yl}-2-(3-trimethylsilanyl-ethylcarboxyamino)-propionic acid methyl ester (7) has been prepared via alkylation of the histidine urea derivative (7S )-5,6,7,8-tetrahydro-7-(methoxycarbonyl)-5-oxoimidazo-[1,5-c]-pyrimidine (2) with Fmoc-protected 3-iodopropyl-amine, followed by ring opening with 2-trimethylsilylethanol. After Fmoc cleavage by HNEt 2 , the histidine amine derivative was coupled to biotin, to the pentapeptide leucine-enkephalin and to Vitamin B12-b-acid by amide formation, employing TBTU as the coupling reagent. In order to make the histidine accessible for labelling, the teoc protecting group was removed by either 
Introduction
The labelling of biologically active molecules with 99m Tc is a field of intense research, [1] [2] [3] [4] as 99m Tc is one of the most widely employed isotopes for imaging in nuclear medicine. This is due to the favourable properties of this isotope: the emission of a 140 keV -ray with an abundance of 89% and a half-life of 6.02 h. In the past compounds with 99m Tc in an almost exclusively +V oxidation state have been used for labelling purposes but recently the 99m Tc(CO) 3 + core in which the oxidation state is +1 has attracted much attention. Three reasons account for this interest: 1) the robustness of complexes with this core, 2) the high affinity of the Tc(I) ion to a large variety of donor atoms and 3) the easy preparation of the precursor [ 99m Tc(H 2 O) 3 (CO) 3 ] + . In fact, GMP produced kits for preparing [ 99m Tc(H 2 O) 3 (CO) 3 ] + are now commercially available (Isolink from Malinckrodt, Inc.), which is expected to furnish the way towards commercial applications. 5 To avoid dissociation of the metal ion from the bioconjugate in biological systems, the ligand covalently attached to the biomolecule should bind as tight as possible to the "fac-[ 99m Tc(CO) 3 ] + " moiety. On the basis of thermodynamic considerations a tridentate ligand is preferred. It forms highly robust complexes and also prevents cross-metalation to ligands present in blood plasma, in particular to those with sulfur or aromatic nitrogen donors. A 99m Tc(CO) 3 complex with a tridentate ligand is less prone to undergo such a undesired reaction due to its coordinative saturatation and because thermodynamic factors strongly disfavour the dissociation of one donor atom from the tridentate ligand.
It is often important for the biological activity of a labelled compound that the overall charge does not change, hence a monoanionic tridentate ligand is required for the fac-[ 99m Tc(CO) 3 ] + core. Systematic investigations about the in vitro and in vivo properties of a variety of complexes containing the Tc(CO) 3 and Re(CO) 3 groups 6, 7 showed that histidine in particular forms complexes of high (biological) stability. [8] [9] [10] Furthermore, histidine is very attractive for labelling with [ 99m Tc(H 2 O) 3 (CO) 3 ] + , since short reaction times (30 min) at relatively low temperatures (50 °C) and ligand concentration result in quantitative labelling yield, making it ideally suited for radiopharmaceutical applications. Another virtue of the histidine ligand is its chirality, which implies that the formed Tc(His-N  -R)(CO) 3 complex moiety will be enantiomerically pure if enantiomerically pure histidine is used.
In contrast, other favourable mono-anionic ligands with a NNO donor set such as the pama-ligand ([pyridine-2-ylmethyl)-amino]-acetic acid) will always lead to a racemic complex. 11 In combination with chiral biomolecules, mixtures of diastereomers will result, which should be avoided for pharmaceutical applications in particular.
The favourable coordination properties of histidine to the different organometallic Mo(-allyl)(CO) 2 core, and the facile derivatisation of Mo(His)(-allyl)(CO) 2 by alkylation of the imidazole N  -atom have been previously reported by van Staveren and Metzler-Nolte in a series of papers. [12] [13] [14] [15] In addition it was shown that the Mo(-allyl)(CO) 2 complex can be attached to the N-terminus of a peptide as a last step of a solid phase synthesis protocol. 14 Recently we reported the carboxylic acid histidine derivative methyl 1-(2-tert-butoxy-2-oxoethyl)-N-(9H-fluoren-9-ylmethox ycarbonyl)histidinate (1) which was coupled to the amino group of phenylalanine by employing standard peptide chemistry methods. 16 After deprotection histidine served as an efficient ligand for 99m Tc(CO) 3 . Since it is often desired to attach the bifunctional chelator to the C-terminus of e.g. a peptide we extend this study by introducing an amino group for coupling to the carboxylate of biomolecules. We report in the present work the synthesis of a protected histidine derivative with an amino group attached on an alkyl chain to the N  -atom (7) . Although seemingly straightforward, the introduction of such a linking group is not routine due to the reactivity of the histidine precursor. The -amine protecting group can be removed either under acidic or Lewis basic conditions which is important in case of sensitive biomolecules. To exemplify the versatility of this approach we show the convenient coupling of this compound to vitamin B12, enkephalin and biotin, biomolecules of varying complexity. Furthermore, we demonstrate that the derivatised biomolecules can be efficiently labelled with [ 99m Tc(OH 2 ) 3 (CO) 3 ]
+ under mild conditions. † Electronic supplementary information (ESI) available: complete 1 H and 13 C NMR spectra of 14, 15, 16 and 19. See http://www.rsc.org/suppdata/ob/ b4/b405575f/ and to elucidate the X-ray structure. An ORTEP presentation is given in Fig. 1 , confirming the molecular structure of the ligand.
During the reaction or column-chromatographic purification over silica elimination of CO 2 and formation of a benzyl-cation (or tropylium ion) occurred. This cation presumably reacts with the N  -atom to form compound 5. The benzyl group is known to have a preference for the His-N  atom and, in fact, this benzyl moiety is a common protecting group for the N  of His in peptide chemistry. [17] [18] [19] To circumvent the CBz protecting group, we examined other N-alkylation reagents with ethyl and propyl spacers and with protecting groups compatible with Fmoc deprotection of N  . The compounds Boc-NHCH 2 CH 2 I, Trt-NHCH 2 CH 2 I and the propyl derivatives Boc-NH-CH 2 CH 2 CH 2 Br and Trt-NH-CH 2 CH 2 CH 2 I were prepared from the corresponding alcohols but all alkylation reac-
Results and discussion

Synthesis
Histidine as a very efficient ligand is the focus of our interest and our aim was a derivative with an additional amine group linked by an alkyl chain to the N  -atom in the imidazole side chain. This amine group enables ligand conjugation to a carboxylate in biomolecules. The approach is complementary to the one employing 1, but the N-terminus of a peptide is usually buried in the core of the protein.
With the new method, conjugation of histidine to the C-terminus, which is usually on the exterior of the protein, is possible.
A general structure of our target compound as well as a retrosynthetic analysis is shown in Scheme 1. The -amine and the amine moiety on the alkyl-chain carry orthogonal protecting groups. In analogy with the synthesis of 1, we planned alkylation of the N  -atom in the urea-protected derivative 2, yielding a cationic intermediate. Subsequent ring opening of the urea moiety with an alcohol will then give the desired but still protected compound (Scheme 1). Although this synthetic pathway seems straightforward we encountered a number of unexpected difficulties, which will be discussed in brief below.
Originally we envisaged to perform the ring opening of the cationic urea derivative with (9H-fluoren-9-yl)-methanol to yield an -amine Fmoc protected derivative. Therefore we concentrated on alkylation of the N  with protected iodo-alkylamines that would resist the conditions required for Fmoc cleavage. In the light of later biomolecule coupling, a short linker between histidine and the biomolecule is preferable and we started with an ethyl spacer. The iodide CBz-NH-CH 2 CH 2 I (4) was synthesised from the corresponding alcohol 3 by using triphenylphosphine, imidazole and iodine (see Scheme 2) . Subsequently histidine-urea derivative 2 was reacted with 4, followed by urea-opening with (9H-fluoren-9-yl)-methanol. Surprisingly, the compound isolated after work-up was not the expected CBz derivative, but compound 5 (see Scheme 2) . The constitution of the molecule was clearly established from the mass spectrum as well as from the 1 H and 13 C NMR spectroscopic data. In addition it was possible to coordinate the ligand to Tc(CO) 3 that small amounts of water in combination with reaction temperatures of 70 °C lead to cleavage of the methyl ester. This concerted cleavage is ideal because both protecting groups are released in the same synthetic step, making the histidine now accessible for labelling.
To more generalize the approach we moved on to the attachment of 8 to a receptor-binding peptide. Leucine-Enkephalin, a pentapeptide with the sequence H-Tyr-Gly-Gly-Leu-Phe-OH was chosen. This pentapeptide was first isolated as a mixture with its position 4 methionine analogue by Hughes et al. in 1975 from pig brain. 21 The presence of this peptide was later also demonstrated in various human tissues, such as the human brain, the human spinal fluid and in blood plasma. It has an action similar to morphine, exhibiting a high affinity for the opioid receptor and acting as a natural pain killer. 22 The protected derivative Boc-(Tyr-OtBu)-Enk-OH (11) was prepared on a resin with a 2-Cl-trityl linker via standard peptide solid phase techniques. The peptide can be cleaved under mildly acidic conditions from the resin, leaving the acid sensitive side-chain protecting groups unaffected. In a next step compound 8 was reacted with 11 employing TBTU as the coupling reagent, which furnished in a clean reaction the expected conjugate 12 after preparative HPLC purification (Scheme 5). The Boc, tert-butyl ether and the teoc group were then simultaneously removed in one step by the reaction with TFA in CH 2 Cl 2 , to afford the fully deprotected peptide 13 in higher than 97% purity. The HRMS and NMR spectroscopic data are consistent with the proposed constitution.
As an example for a more complex and biologically important molecule belonging to a different category, we selected vitamin B12 or cobalamin. Vitamin B12 is necessary for the proper function of the nervous system and for the metabolism of carbohydrates, proteins and fat and it is also involved in the reductive conversion of ribonucleotides to deoxyribonucleotides to generate DNA. 23, 24 Vitamin B12 comprises amides, benzimidazole, phosphate esters and other groups which are potentially coordinating for the [Tc(CO) 3 ] + moiety. Strong ligands are required in order to yield one well-defined product.
Cobalamin contains five terminal amide groups, but no free carboxylate as required for its coupling to the amine in 8. According to a literature procedure aqueous acid hydrolysis of vitamin B12 yields a mixture of mono and di-acids. The vitamin B12 compound in which the b-amide is hydrolyzed represents the main hydrolysis product in this reaction (Scheme 6). [25] [26] [27] The b-acid can be separated by means of ion-exchange column chromatography and preparative HPLC in approximately 15% yield.
The coupling of the amine histidine derivative 8 with vitamin B12-b-acid 14 does not require pure 8. Instead freshly deprotected 7 was reacted with 14 in a DMSO/DMF mixture with TBTU as the coupling reagent. With preparative HPLC the teoc-protected B12-histidine conjugate 15 (Scheme 6) was conveniently separated from the side products that originated from the Fmoc cleavage. These tions with 2 were unsuccessful. After heating at reflux for several days, no new compounds could be identified.
To increase reactivity, we then switched to iodo-alkyl amines protected by an Fmoc group, well aware that this strategy would require a different alcohol for ring opening of the cationic urea intermediate in order to ensure orthogonality between the two amine protecting groups. The alcohol 2-trimethylsilylethanol fulfils this condition ideally since the 2-trimethylsilylethylcarbonyl (teoc) protecting group is stable under basic conditions and can be cleaved both under Lewis basic conditions employing fluoride ions or under acidic conditions by using trifluoroacetic acid. 20 The iodo derivatives Fmoc-NH-CH 2 CH 2 I and Fmoc-NH-CH 2 CH 2 CH 2 I (6) were prepared from the corresponding primary alcohols. Upon reaction of 2 with Fmoc-NH-CH 2 CH 2 I, only small amounts of a new product could be observed after a reflux period of 5 days but over 2 weeks 2 decomposed slowly. In contrast, refluxing 6 with 2 already led to the formation of a significant amount of a new product after a reflux period of only 24 h. The reaction was complete after 4.5 days. Compound 6 represents the only alkylating agent giving a clean reaction with 2 and affording the introduction of the desired -NH 2 group. Subsequent ring opening of the cationic urea derivative with 2-trimethylsilylethanol afforded overnight the fully protected histidine amine derivative 7 in a 53% yield (two steps) as shown in Scheme 3. Cleavage of the Fmoc group in 7 could be achieved by treatment with HNEt 2 in DMF (Scheme 4) and pure 8 could be obtained after purification with preparative HPLC. Principally, conjugation of 8 to biomolecules can be performed after in situ preparation of 8 from 7 but sometimes purification of the resulting bioconjugate is complicated by the presence of fulvene derivatives from the Fmoc cleavage.
This synthetic approach now allows the preparation of large amounts of histidine amine derivative 7 or 8 respectively. The next step consisted of the selection of carboxylic acid-containing biomolecules interesting for labelling from a radiopharmaceutical point of view. To show that histidine can be introduced in a variety of biomolecules we selected diverse biomolecules to demonstrate the general versatility of the coupling method with the histidine derivative. Biotin was chosen since its labelling is of ongoing interest in radiopharmacy, enkephalin since it represents a less known biomolecule from the general class of peptides and vitamin B12 as a more complex system with integrated potentially coordinating functions. As for biotin, labelled vitamin B12 is also of strong interest for cancer diagnosis and therapy in nuclear medicine.
D-(+)-Biotin, also called vitamin H, was conveniently coupled to 8 by using TBTU. The purification via an extractive work-up proceeded smoothly, affording compound 9 in pure form. Removal of the teoc protecting group was achieved by the reaction of 9 with NBu 4 F in THF/DMF. These conditions hydrolyzed also simultaneously but unexpectedly the methyl ester and afforded 10 (Scheme 4) in good yield as derived from the MS and NMR spectroscopic data. Since the fluoride ion is a strong Lewis base, it is conceivable + the teoc protecting group had to be removed. The fluoride method, e.g. the reaction with NBu 4 F or CsF, was not successful and stirring of 15 in the presence of either fluoride source in DMF at RT decomposed B12, as is obvious from an irreversible colour change from red to purple. Quantitative cleavage of the teoc group could only be achieved by stirring 15 in a TFA/CH 2 Cl 2 (4/1) mixture at 0 °C for 4. Comparison of the NMR spectra of the B12-conjugates with those of the starting material, the vitamin B12-b-acid 14, gives clear evidence for the formation of the expected species. Labelling. To identify labelled compounds, it is common in radiopharmaceutical chemistry to compare the retention time in the HPLC radiochromatogram with the UV/Vis trace of the corresponding non-radioactive Re congener. Since 99m Tc labelled compounds are present in a concentration of about 10 −7 M, radiochromatography is the only way of characterization. Correspondingly, before labelling the bioconjugates with [ 99m Tc(OH 2 ) 3 (CO) 3 ] + the "cold" Re(CO) 3 analogues were synthesized and accurately characterized. In particular, our interest concerned the shift in retention times in the HPLC chromatograms between the conjugates with and without the Re(CO) 3 moiety. The Re analogues can principally be prepared along two different pathways. The bioconjugates 10, 13 or 16 are either simply reacted with [Re(OH 2 ) 3 (CO) 3 ] + or the complex with the linking moiety is prepared first and then conjugated to the corresponding biomolecule. Obviously, the same product should be received for both methods. We adapted the former method for Re labelling of 13 only, since the latter method lead to a mixture of compounds difficult to separate. Correspondingly, the complex Re(His-N  -(CH 2 ) 3 -NHBoc)(CO) 3 (17) (Scheme 7) was used as the starting material for preparation of the Re(His)(CO) 3 derivatized biotin and vitamin B12 conjugates. Compound 17 was synthesised via a straightforward alkylation of Re(His)(CO) 3 with Boc-NH-CH 2 CH 2 CH 2 -Br in DMF in the presence of solid Cs 2 CO 3 . This method has been previously reported for the alkylation of Mo(His)(allyl)(CO) 2 and Re(His)(CO) 3 . 12, 13, 16 The Boc-protecting group was then removed by stirring 17 in a 2/1 CH 2 Cl 2 /TFA mixture at 0 °C for 1 h. To avoid decomposition, the temperature should not exceed 0 °C and removing the solvent in vacuo should be performed without external heating.
The biotin-His-Re(CO) 3 conjugate (18) was synthesised by reacting deprotected 17 with biotin in DMF in the presence of TBTU and purified by column chromatography. Accordingly, the vitamin B12 conjugate 19 was synthesised and purified by preparative HPLC. 3 ] in 1 M NaHCO 3 at 60 °C for 1 h we observed a new peak with a retention time slightly higher than the starting material (see Table 1 ). The ratio between the new peak and the starting material was about 3/1 and unfortunately they could not be separated by preparative HPLC.
Subsequently we investigated the labelling efficiency of the coupled histidine ligand under various conditions with 99m Tc. Model reactions with histidine showed that quantitative complex formation can be achieved at histidine concentrations as low as 10 −6 M after 30 min at 95 °C. Heating is required to accelerate the reaction at such a high dilution. It is characteristic for the thermal stability of carbonyl complexes that no decomposition is found even after prolonged boiling in phosphate buffer. However, since some biomolecules do not thermally resist such conditions, more moderate conditions and, correspondingly, reactions at higher concentrations or longer time have to be employed.
Labelling + had disappeared completely and the formation of one single new peak could be observed in the radiochromatogram. The labelling yield was quantitative for all bioconjugates. The retention times for the native biomolecules, the unlabelled conjugates, the "cold" Re(CO) 3 conjugates and the 99m Tc labelled molecules are given in Table 1 . The retention times will be discussed below.
It should be emphasized at this point that the efficiency of labelling the histidine ligand in its carboxylic acid form (10) + and the difference, if any, might only manifest itself at lower reaction times or lower temperatures. Consequently for practical purposes the methyl ester form and the carboxylic acid form are equally suited for labelling. Probably, hydrolysis of the ester is metal mediated. Once the Tc centre is bidentate coordinated, the ester is activated towards hydrolysis due to its close proximity to the metal and the preorientation for tridentate coordination. This is an important finding, because: 1) it saves a reaction step in some synthetic sequences and 2) it permits the labelling of biomolecules that do not withstand strongly alkaline conditions, such as the B12-conjugate 16.
For the most sterically demanding conjugate, the vitamin B12 compound 16, we investigated the accessibility of the histidine moiety for labelling as well. Steric accessibility of the chelators in general in 16 might be a limiting factor in the labelling process. Labelling yields with 16 at 10 −5 M were therefore compared with those for free histidine at the same concentration. Histidine converts completely in the complex 99m Tc(His)(CO) 3 after 30 min at 50 °C and the behaviour observed for a 10 −5 M solution of 16 was identical, complete conversion after a period of 30 min at 50 °C. These results demonstrate that histidine attached to the bulky vitamin B12 is not significantly different in its reactivity than free histidine.
The chromatographic behaviour of unlabelled and 99m Tc or Relabelled conjugates as shown in Table 1 represents important information about hydro-/lipophilicity of biologically active compounds. The comparable retention times of "cold" Re(CO) 3 and 99m Tc(CO) 3 derivatives confirm the identity of the compounds. The differences between Re(CO) 3 and 99m Tc(CO) 3 derivatives are explained by the separation of the UV/Vis and the radiodetector. It is common to all three labelled compounds that their retention times are larger than those of the native molecules. Unless the overall charge is changed, this is a common feature observed in labelling and not related to the fac-[ + moiety alone. It indicates increased lipophilicity which is distinct in case of biotin (8.9 vs. 16.5 min) and less significant in case of enkephalin and vitamin B12. Since molecular size is also relevant to understanding the delayed retention times and biotin is small in comparison to enkephalin and vitamin B12, the delay should not exclusively be interpreted in terms of lipophilicity. We emphasize that labelled and unlabelled enkephalin and vitamin B12 are not very different and that their in vivo behaviour should therefore be similar. 
Conclusion
Experimental
IR spectra were recorded on a Bio-Rad FTS-45 spectrometer with the samples in compressed KBr pills. Electrospray ionisation mass spectra (ESI-MS) were recorded on a Merck Hitachi M-8000 spectrometer in the positive ion mode using methanol as the solvent. Fast Atom Bombardment (FAB, nitrobenzylalcohol as matrix)) mass spectra, both at low and high resolution, were recorded on a Jeol JMS-700 mass spectrometer. As reference compounds for the high resolution FAB mass spectra PEG's of a suitable mass were used. For the Re compounds, only the values of the 187 Re isotope are reported in the low resolution mass spectra, whereas in high resolution mass spectra peaks originating from both the 185 HPLC analyses were performed on a Merck-Hitachi L-7000 system equipped with a EG&G Berthold LB 508 radiometric detector, using Waters XTerra RP8 columns (5 m particle size, 1 × 100 mm) and a flow rate of either 0.5 ml min −1 or 1 ml min −1
. Chromatograms were recorded at 220, 250 and 360 nm. Sodium acetate buffer a) was prepared by mixing 2.9 ml acetic acid and 4.55 ml sodium hydroxide 2 M in 900 ml water and 100 ml methanol. Tris buffer a) was prepared by dissolving tris(hydroxymethyl)aminomethane (6.05 g) in water, adding HCl 2 M to reach a pH of 8.2, adjusting the volume to 1000 ml, and adding acetonitrile (10 ml). TFA buffer a) was prepared by dissolving 1.0 ml of CF 3 COOH in 1000 ml of water. Buffer b) was always methanol. Preparative HPLC separations were performed on a Varian Prostar system equipped with two Prostar 215 pumps and a Prostar 320 UV/Vis detector, using a Waters XTerra Prep RP8 column (5 m particle size, 30 × 100 mm) or a Macherey-Nagel Nucleosil C-18ec column (7 m particle size, 100 Å pore size, 40 × 250 mm). Flow rates were 30 ml min −1 for the RP8 30 × 100 mm column and 40 ml min −1 for the C-18ec column. After the preparative HPLC purification, cobalamin derivatives were desalted by applying an aqueous solution of the compound to a Chromafix RP18ce cartridge, followed by thoroughly rinsing with water. The desalted product was then eluted with methanol, the solvent was removed in vacuo, and the product was dried under high vacuum. The biotin and enkephalin derivatives purified by preparative HPLC were isolated by removing the methanol portion of the eluent in vacuo, followed by lyophilisation. 3 ] labelled bioconjugates, which was demonstrated by HPLC with radioactive detection. For the HPLC analysis of labelled 10 or 13, the TFA buffer as buffer a) (described above) was used with the C8 column. The following program was used: from 0 to 3 min only the TFA buffer. At 3.1 it jumped to 25% MeOH, which was then kept constant for 6 min. At 9 min a jump to 33% MeOH is followed by a linear gradient to 100% MeOH from 9.1 min to 20 min. For the analysis of labelled 16, the NaOAc buffer (described above) was used as buffer a) with the C8 column. The following program was used: from 0% to 15% MeOH in 30 min, then the MeOH content increased to 100% over 10 min. 33 To a solution of 3-aminopropanol (4.0 ml; 3.93 g; 15.7 mmol) in MeCN (20 ml) was added chlorotriphenylmethane (2.0 g; 7.2 mmol). After the mixture was stirred for 30 min at RT, it was poured into 200 ml of H 2 O and stirred for 10 min. During this time a white precipitate formed, which was isolated by filtration and dried in vacuo. The white solid was dissolved in 60 ml anhydrous diethyl ether and gaseous HCl was bubbled through the solution, resulting in the formation of a finely divided white precipitate. It was isolated by filtration, washed with Et 2 O and air-dried. Yield: 2.15 g; 85%.
General
Synthesis
Found: C, 74.7; H, 6.9; N, 3.9; Calc. for C 22 To a solution of triphenylphosphine (786 mg; 3.0 mmol) and imidazole (204 mg; 3.0 mmol for the synthesis of 4, Fmoc-NH-CH 2 CH 2 I and 6; 408 mg; 6.0 mmol for the synthesis of Trt-NH-CH 2 CH 2 I and Trt-NH-CH 2 CH 2 CH 2 I) in dry CH 2 Cl 2 (50 ml) under N 2 was added in small portions I 2 (837 mg; 3.0 mmol) over a period of 5 min. The mixture was stirred for 15 min at RT and subsequently cooled to 0 °C. After the corresponding alcohol derivative was added as a solid, the suspension was stirred at 0 °C for 15 min and then stirred at RT for 1 h. The mixture was filtered to remove a white solid, followed by evaporation of the solvent under reduced pressure. After purification by column chromatography (silica; hexane/EtOAc 2/1), the iodide was isolated in a 75-92% yield as a colourless solid. 
3-(1-Benzyl-1H-imidazol-4-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-propionic acid methyl ester (5)
A mixture of 2 (196 mg; 1.0 mmol) and 4 (610 mg; 2.0 mmol) in MeCN (40 ml) was heated at reflux for 16 h under an atmosphere of N 2 . TLC showed that the starting urea derivative had completely reacted. The mixture was concentrated in vacuo, resulting in a white solid. This solid was washed with dry Et 2 O (3 × 20 ml) to remove excess 4. The solid material was redissolved in MeCN (40 ml) and 9-fluorenylmethanol (588 mg; 3.0 mmol) and dipea (581 mg; 4.5 mmol) were added. The resulting mixture was stirred at RT under N 2 for 16 h. The solvent was removed in vacuo, followed by purification by column chromatography (silica; CH 2 ).
99 Tc(His-N  -benzyl)(CO) 3 A solution of 40.4 mg (0.084 mmol) 5 was dissolved in CH 2 Cl 2 (2 ml) and TFA (1.5 ml) was added. The mixture was stirred for 1.5 h followed by removal of the solvent in vacuo. The residue was dissolved in H 2 O (2 ml) and (NEt 4 ) 2 [TcBr 3 (CO) 3 ] was added. The pH was adjusted to 7 by carefull addition of a 1 M NaOH solution. The mixture was allowed to stir overnight, during which time a white/creamy precipitate formed. The solid was isolated by filtration, washed with H 2 O and air dried. Yield: 26 mg (72%)
3-{1-[3-(9H-Fluoren-9-ylmethoxycarbonylamino)-propyl]-1H-imidazol-4-yl}-2-(3-trimethylsilanyl-ethylcarboxyamino)-propionic acid methyl ester (7)
A mixture of 2 (196 mg; 1.0 mmol) and 8b (1.22 g; 3.0 mmol) in MeCN (40 ml) was heated at reflux for 4.5 days under an atmosphere of N 2 . TLC showed that the starting urea derivative had completely reacted. The mixture was concentrated in vacuo, resulting in a white solid. The solid material was redissolved in MeCN (40 ml) and 2-trimethylsilylethanol (355 mg; 3.0 mmol) and dipea (259 mg; 2.0 mmol) were added. The resulting mixture was stirred at RT under N 2 for 16 h. The solvent was removed in vacuo, followed by purification by column chromatography (silica; EtOAc). 
3-[1-(3-Amino-propyl)-1H-imidazol-4-yl]-2-(3-trimethylsilanyl-ethylcarboxyamino)-propionic acid methyl ester (8)
Compound 7 (255 mg; 0.43 mmol) was dissolved in a 1/1 DMF/ NEt 2 mixture (8 ml). After the mixture was stirred for 1 h at RT, the solvent was removed in vacuo. Purification by preperative HPLC (C-18ec column; TFA buffer) afforded 8 as a colourless foamy solid as its trifluoroacetate salt. 
Biotin conjugate 9
D-(+)-Biotin (35 mg; 0.14 mmol) was dissolved in a 4/1 (v/v) mixture of DMF/NEt 3 (2.5 ml). To this mixture a solution of 8 (91 mg; 0.19 mmol) was added in DMF (2 ml), followed by addition of TBTU (46 mg; 0.14 mmol). After stirring for 45 min at RT, it was evaporated to dryness in vacuo. The residue was taken up in 2 M NaHCO 3 (20 ml) and extracted with CH 2 Cl 2 (3 × 20 ml). The combined organic layers were washed with 0.5 M HCl (20 ml), H 2 O (20 ml) and brine (2 × 20 ml). After removal of the solvent, 9 was obtained as a colourless foamy solid. Yield: 67 mg (78%; relative to biotin). CO amide ), 138.5, 138.3, 118.7 (ArC His ), 64.2, 64.4, 61.7,  57.1, 55.7, 52.8, 45.7, 41.1, 37.4, 36.8, 31.9, 31.1, 29.8, 29.5, 26.8 
Biotin conjugate 10
To a solution of 9 (100 mg; 0.17 mmol) in DMF (5 ml) was added 1 ml of a 1 M NBu 4 
Boc-(Tyr-tBu)-Gly-Gly-Phe-Leu-OH (11)
The synthesis of Boc-Tyr(tBu)-Gly-Gly-Phe-Leu-OH was performed via solid phase peptide synthesis methods, adapting the Fmoc strategy. The H-Leu-2-ClTrt resin was obtained from Advanced ChemTech and had a loading of 1.3 mmol g −1 with a mesh-size of 100-200. All coupling reagents and amino acids were purchased from Novabiochem and used without further purification.
Coupling reactions were performed with 5 equivalents of amino acid and HOBt and 4.9 equivalents of TBTU for 30 min in DMF. Deprotection was performed twice for 5 min using 20% piperidine in DMF. After complete assembly, the product was cleaved from the resin by 1% TFA in DCM, containing 3% of triisopropylsilane as a scavenger. After evaporating the solvents the crude product was repeatedly washed with cold ether and subsequently lyophilised. 
Enkephalin conjugate 12
To a solution of purified 8 (39 mg; 0.08 mmol) and 11 (85 mg; 0.08 mmol) in DMF (1.5 ml) and NEt 3 (0.5 ml) was added TBTU (25 mg; 0.08 mmol). The mixture was stirred for 45 min at RT and concentrated to dryness in vacuo. The compound was purified by two consequetive HPLC runs (run 1: C8-column; 50 mM TRIS buffer; run 2: C8-column; TFA buffer 155.4, 138.3, 136.4, 133.6, 130.9, 130.2, 129.6 
Vitamin B12-b-acid; cyanocobalamin b-monocarboxylic acid (14)
Vitamin B12 (1.88 g, 1.39 mmol) was hydrolyzed in HCl 0.1 M (190 ml) as described in the literature. [25] [26] [27] The purification was modified in the following way: the Dowex column allowed, after desalting by phenol extractions, the isolation of three fractions, one containing exclusively d-acid, a second one consisting of a mixture of b-acid and d-acid, and a third fraction consisting of a mixture of b-acid and e-acid. The mixture of b-acid and d-acid was separated by preparative HPLC (column: Waters XTerra Prep RP8, 5 m, 30 × 100 mm; buffer a: acetate buffer; gradient: 0.5% min −1 starting from 100% buffer a). The mixture of b-acid and e-acid was separated analogously but using the Tris buffer as buffer a. Cyanocobalamin-b-acid was isolated in a yield of 280 mg (15%). 
Vitamin B12-b-acid conjugate 15
Compound 7 (44 mg; 0.07 mmol) was dissolved in DMF (1.5 ml) and Et 2 N (1.5 ml). The mixture was stirred for 1 h at RT. Subsequently the mixture was evaporated to dryness in vacuo. In another flask, 14 (20.0 mg, 14.8 mol) was dissolved in 4.5 ml of a DMSO/ DMF (1/5 v/v) mixture. This mixture was transferred to the flask containing the deprotected histidine derivative. Subsequently NEt 3 (1.0 ml) and TBTU (32.1 mg; 0.1 mmol) were added. The mixture was stirred for 45 min at RT, after which period it was concentrated to dryness in vacuo. Purification by preparative HPLC (C8-column; acetate buffer; gradient: 2.0% per min, starting from buffer a) afforded 16 mg (67%) of a red solid. 50.0, 48.6, 47.0, 45.7, 44.1, 43.1, 40.3, 37.7, 36.7, 35.5, 33.6,  33.2, 33.1, 32.5, 32.5, 32.1, 31.4, 29.8, 27.6, 27.5, 21.1, 20.7, 20.5 
Re complex 17
To a solution of Re(His)(CO) 3 (178 mg; 0.4 mmol) and Boc-NH-CH 2 CH 2 CH 2 Br (100 mg; 0.4 mmol) in DMF (4 ml) was added Cs 2 CO 3 (140 mg; 0.4 mmol). The resulting suspension was heated at 40 °C for 16 h. After the solvent was removed in vacuo, the residue was taken up in CH 2 Cl 2 (25 ml) and H 2 O (20 ml). The phases were separated and the aqueous solution was extracted with CH 2 Cl 2 (25 ml). The CH 2 Cl 2 were combined and washed with brine (2 × 20 ml) and dried (MgSO 4 
Biotin conjugate 18
To a solution of complex 17 (98 mg; 0.17 mmol) in CH 2 Cl 2 (4 ml) at 0 °C was added TFA (2 ml). The mixture was stirred for 1 h at 0 °C, followed by removal of the solvent in vacuo. In a separate flask D-(+)-biotin (41 mg; 0.17 mmol) was dissolved in a 4/1 (v/v) DMF/NEt 2 solution. This mixture was added to the Re complex and TBTU (55 mg; 0.17 mmol) was added. After it had been stirred at RT for 45 min, the mixture was evaporated to dryness in vacuo. The sticky residue was washed with EtOAc (2 × 50 ml) and H 2 O (2 × 10 ml to remove some side-products. The residue was dissolved in a minimum amount of MeOH and subsequently purified by column chromatography (EtOH 
Vitamin B12-b-acid conjugate 19
To a solution of complex 17 (40 mg; 0.07 mmol) in CH 2 Cl 2 (2 ml) at 0 °C was added TFA (1 ml). The mixture was stirred for 1 h at 0 °C, followed by removal of the volatiles in vacuo. In a different flask 14 (20.0 mg, 14.8 mol), was dissolved in DMSO (0.8 ml). Subsequently were added DMF (2 ml) and NEt 3 (0.1 ml). The mixture was transferred to the flask containing the Re complex and TBTU (32.1 mg; 0.1 mmol) was added. After stirring at RT for 45 min, the solvent was removed in vacuo. CCDC reference number 236282. See http://www.rsc.org/ suppdata/ob/b4/b405575f/ for crystallographic data in .cif or other electronic format.
